A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

ovartis Vaccines and Diagnostics S.r.l.0 个研究点开始时间: 2013年5月6日最近更新: 2015年12月22日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male and female children between 12 months and 15 months old inclusive (minimum 365 days of age and maximum 15 months plus 29 days of age), who were born with an estimated gestational age = 37 weeks;
•2. For whom parent(s)/legal guardian(s) have given written informed consent after the nature of the study has been explained according to local regulatory requirements;
•3. Who the investigator believes that their parents/ guardians will be available for all the visits and would comply with the requirements of the protocol (e.g., completion of the Diary Cards, availability for study visits / safety phone calls);
•4. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 200
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Subjects that had a previous confirmed or suspected disease caused by N. meningitidis.
•2. Who were previously exposed to clinically proven meningococcal disease or clinical bacterial meningitis without further microbiologic characterization, i.e. possible meningococcal disease.
•3. Who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational).
•4. Who have received within 90 days prior to enrollment or are expected to receive during the study period any investigational or non-registered product (drug or vaccine).
•5. Who have received or who are planning to receive any vaccines within 14 days before and 30 days after administration of the study vaccine (Exceptions: Injectable influenza vaccine may be administered up to 14 days prior to study vaccination and at least 14 days after study vaccination).
•6. Who have a major congenital defect or a serious chronic disease.
•7. Who have a history of any anaphylaxis, severe vaccine reactions, or allergy to any vaccine components including diphtheria toxoid (CRM197) or tetanus toxoid (TT) and latex.
•8. Who required chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the study vaccination. (For corticosteroids, this means prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
•9. Who received immunoglobulins and/or any blood products within six months prior to study vaccination or who have administration planned during the study period.
•10. Who have any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
•11. Who have any bleeding disorder which is considered as a contraindication to intramuscular injection.
•12. Who have experienced a moderate or severe acute infection and/or fever (defined as temperature >= 38°C) within 3 days prior to enrollment.
•13. Who have received systemic antibiotic treatment within 7 days prior to enrollment.

研究者

发起方

ovartis Vaccines and Diagnostics S.r.l.

相似试验

进行中（未招募）

1 期

A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects toddlers aged 12 <18months or 18 < 24 months.Invasive meningococcal disease (IMD) caused by Neisseria meningitidisserogroup BMedDRA version: 20.0Level: PTClassification code 10027249Term: Meningitis meningococcalSystem Organ Class: 10021881 - Infections and infestations

EUCTR2011-004400-38-PLPfizer Inc, 235 East 42nd Street, New York, NY 10017396

进行中（未招募）

1 期

EUCTR2011-004400-38-CZPfizer Inc396

进行中（未招募）

1 期

EUCTR2011-004400-38-FIPfizer Inc, 235 East 42nd Street, New York, NY 10017396

进行中（未招募）

1 期

Study conducted in healthy adolescents to evaluate safety and antibody response after the administration of different schedules of a vaccine produced by Novartis Vaccines and Diagnostics compared to Novartis Meningococcal group B vaccineand and directed against Meningococcal serogroup A, B, C, Y and W strains.The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination.MedDRA version: 19.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestations

EUCTR2013-002451-15-PLGlaxoSmithKline Biologicals SA1,050

进行中（未招募）

1 期

Study conducted in healthy adolescents to evaluate safety and antibody response after the administration of different schedules of a vaccine produced by GSK Vaccines and Diagnostics compared to GSK Meningococcal group B vaccineand and directed against Meningococcal serogroup A, B, C, Y and W strains.

EUCTR2013-002451-15-FIGlaxoSmithKline Biologicals SA1,050